Edison Investment Research - AROVELLA THERAPEUTICS LTD (ALA) Arovella Therapeutics - Acquiring DKK1 rights

Report

Edison Investment Research

Sean Conroy

Arovella Therapeutics - Acquiring DKK1 rights

Arovella Therapeutics (formerly SUDA Pharmaceuticals) has announced it has in-licensed the rights to a novel monoclonal antibody that targets the Dickkopf-1 (DKK1) peptide from MD Anderson Cancer Center (for undisclosed upfront and development milestones as well as single digit royalties). DKK1 has been shown to promote tumour metastasis across a variety of tumour types. The company plans to combine the DKK1 targeting technology with its recently acquired invariant natural killer T (iNKT) cell therapy platform and test DKK1-CAR-iNKT cells (under programme name ALA-104) in cancer models in 2022.

21/12/2021 1 EN

Underlying

AROVELLA THERAPEUTICS LTD

See profile

AU0000182784 Australian Securities Exchange Australia

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

Edison Investment Research

Arovella Therapeutics - Pending patents reconfirm development of iNKT

In conjunction with Arovella Therapeutics’ strategic focus on developing its invariant natural killer T (iNKT) technology, the company has announced it has received a notification of intention from the European Patent Office for the pending patent grant for its cell platform. Management expects the patent to be granted in early 2023, after completing the formalities. Patent applications have also been filed in the United States, Canada, China, Hong Kong and Australia. If granted, the European patent would be valid until 28 February 2039. This should provide intellectual property protection to ...

November 8, 2022 November 8, 2022 1 EN

Edison Investment Research

Arovella Therapeutics - Strategic refocus on iNKT platform

Arovella has released its activity report for Q123, the key highlight of which was the company’s decision to focus exclusively on its invariant Natural Killer T (iNKT) cell platform and cease R&D operations on its legacy OroMist platform (of which Zolpimist is the flagship asset). We consider this move as sensible as it allows Arovella to focus its resources and efforts to progress its immunoncology franchise following the in-licensing of its iNKT portfolio in mid-2021. We also believe that the decision has been bolstered by the recently announced collaboration agreement with Imugene (which co...

November 3, 2022 November 3, 2022 1 EN

Edison Investment Research

Arovella Therapeutics - Positive collaboration with ALA-101

Arovella has entered into a strategic collaboration with Imugene, investigating the company’s lead cell-therapy programme CAR19-iNKT (ALA-101) with Imugene’s onCARlytics (CF33-CD19) platform in treating solid tumours. The agreement will see both companies jointly conduct pre-clinical studies for the ALA-101/CF33-CD19 combination, with initial results from the animal studies expected in H123. Combinational oncology treatment regimens are often associated with superior clinical outcomes compared to monotherapies, so we see this partnership as highly positive for the development of ALA-101. Addit...

September 27, 2022 September 27, 2022 1 EN

Card Factory - Confident on FY25 outlook

Card Factory’s H125 revenue growth demonstrated it is delivering well against its multi-year growth strategy. While profitability was negatively affected by the (mostly) known inflation in operating costs, management is confident Card Factory will achieve its full-year estimates. This is due the momentum in the business and the mismatch in H125 between cost inflation and the efficiency and cost savings that have always been expected to come through in H225.

October 4, 2024 October 4, 2024 1 EN

Sean Conroy

Sean Conroy

Immix Biopharma - US CAR-T trial progresses to dose expansion

Immix Biopharma’s US-based NEXICART-2 trial continues to make steady progress through the clinic, with the company reporting that the trial has advanced to the dose expansion level of 450m cells, after completing the 150m cell cohort. The Phase Ib/II trial is assessing Immix’s lead CAR-T asset NXC-201 as a first-in-class outpatient treatment for relapsed/ refractory amyloid light chain amyloidosis (r/r ALA). We highlight that both chosen doses in NEXICART-2 trial had elicited complete responses in the prior NEXICART-1 trial, which was based in Israel. We view the latest update as an encouragin...

October 4, 2024 October 4, 2024 1 EN

Pedro Fonseca

Pedro Fonseca

Helios Underwriting - Strategic shift from growth to consolidation

Helios Underwriting (Helios) delivered EPS growth of 35% to 7.7p in H124 and reported a net asset value (NAV) of 191p/share. While its combined ratio of 91.6% deteriorated from 88% in H123 and 85% in FY23 due to seasonal impacts on the 2024 year of account (YOA) and stricter reserving for its 2022 YOA, we forecast an improvement to 88.8% for FY24. Helios experienced cost pressures during the period as a result of abandoning its ‘follow-only’ syndicate initiative and the departure of its CEO. We expect a meaningful reduction in costs in FY25, including a saving in stop-loss reinsurance costs as...

October 3, 2024 October 3, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Arovella Therapeutics - Acquiring DKK1 rights

Arovella Therapeutics - Pending patents reconfirm development of iNKT

Arovella Therapeutics - Strategic refocus on iNKT platform

Arovella Therapeutics - Positive collaboration with ALA-101

Card Factory - Confident on FY25 outlook

Immix Biopharma - US CAR-T trial progresses to dose expansion

Helios Underwriting - Strategic shift from growth to consolidation

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe